Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery: An autoradiographic study in the rat

European Journal of Cancer

Volumn 40, Issue 1, 2004, Pages 142-147

  Mahteme, H ^a   Larsson, B ^b   Sundin, A ^a   Khamis, H ^b   Graf, W ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Intraperitoneal chemotherapy; Peritoneal metastases; Tumour reduction

Indexed keywords

CARBON 14; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COLORECTAL CANCER; COMPARATIVE STUDY; DRUG UPTAKE; FEMALE; IMAGE ANALYSIS; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RANDOMIZATION; RAT; SURGICAL TECHNIQUE; TUMOR GROWTH; TUMOR VOLUME;

EID: 0347627358     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00667-1     Document Type: Article

References (40)

1. Graf W., Glimelius B., Påhlman L., Bergström R. Determinant of prognosis in advanced colorectal cancer. Eur. J. Cancer. 27:1991;119-123.
2. Mahteme H., Påhlman L., Glimelius B., Graf W. Prognosis after surgery in patients with incurabel rectal cancer. a population-based study Br. J. Surg. 83:1996;1116-1120.
3. Shepherd N., Baxter K., Love S. The prognostic importance of peritoneal involvement in colonic cancer. a prospective evaluation Gastroenterology. 112:1997;1096-1102.
4. Assersohn L., Norman A., Cunningham D.et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br. J. Cancer. 79:1999;1800-1805.
5. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. a randomized trial J. Clin. Oncol. 10:1992;904-911.
6. Glimelius B. Biochemical modulation of 5-fluorouracil. a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The gastrointestinal tumour adjuvant therapy group Ann. Oncol. 4:1993;235-240.
7. Scheithauer W., Rosen H., Kornek G.V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 306:1993;752-755.
8. Van Halteren H.K., Roumen R.M.H., Coebergh J.W.W.et al. The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer. Anti Cancer Res. 19:1999;3447-3450.
9. Glimelius B., Jakobsen A., Graf W.et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer. a prospective randomised trial Eur. J. Cancer. 34:1998;674-678.
10. Csoka K., Nygren P., Graf W.et al. Selective sensitivity of solid tumors to suramin in primary c of tumor cells from patients. Int. J. Cancer. 3:1995;356-360.
11. Friborg H., Nygren P., Dhar S.et al. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. J. Exp. Ther. Oncol. 1:1996;286-295.
12. Giaccone G., Pinedo H.M. Drug resistance. Oncologist. 1:1996;82-87.
13. Jain R.K. Determinants of tumor blood flow. a review Cancer Res. 48:1988;2641-2658.
14. Less J., Posner M., Boucher Y.et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 52:1992;6371-6374.
15. Long R.T.L., Spratt J.S. Jr., Dowling E. Pseudomyxoma peritonei. New concepts in management with a report of seventeen patients. Am. J. Surg. 117:1969;162-169.
16. Cunliffe W., Sugarbaker P. Gastrointestinal malignancy. rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy Br. J. Surg. 76:1989;1082-1090.
17. Horsell K.W., Merten S., Clingan P., King D.W., Morrsis D.L. Peritonectomy and intraperitoneal chemotherapy in appendix and colorectal cancer. Aust. N. Z. J. Surg. 69:1999;729-732.
18. Gough D.B., Donohue J.H., Schutt A.J.et al. Pseudomyxoma peritonei, long term patient survival with an aggressive regional approach. Ann. Surg. 219:1994;112-119.
19. Schellinx M.E., von Meyerfeldt M.F., Sugarbaker P.H. Peritoneal carcinomatosis from adenocarcinoma of the colon. Cancer Treat Res. 81:1996;247-260.
20. Steele G. Jr., Sjögren H.O. Cross-reacting tumour-associated antigen(s) among chemically induced rat colon carcinomas. Cancer Res. 34:1974;1801-1807.
21. Graf W., Sundin A., Glimelius B., Ahlström H., Carlsson J. Induction and quantification of hepatic metastases from a human colonic cancer in the nude rat. Eur. J. Surg. Oncol. 18:1992;608-614.
22. Ullberg S., Larsson B., Tjälve H. Autoradiography. Glenn H.J. Biologic Applications of Radiotracers. 1982;55-108 CRC Press, Boca Raton, FL.
23. Dencker L., Larsson B., d'Argy R., Ullberg S., Tjälve H. Macro- and micro-autoradiography. Pure Appl. Chem. 63:1991;1271-1277.
24. d́Argy R., Sperber G., Larsson B., Ullberg S. Computer-assisted quantitation and image processing of whole body autoradiograms. Pharmacological Methods. 24:1990;165-181.
25. Fleiss J.L. The Design and Analysis of Clinical Experiments. 1986;John Wiley & Sons, New York.
26. Santi D.V., McHenry C.S., Raines R.T., Ivanetich K.M. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry. 29:1987;8606-8613.
27. Radparvar S., Houghton P.J., Germain G., Pennington J., Rahman A., Houghton J.A. Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiencey. Biochem. Pharmacol. 39:1990;1759-1765.
28. Chadwick M., Rogers W.I. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Cancer Res. 32:1972;1045-1046.
29. Graf W., Påhlman L., Bergström R., Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br. J. Cancer. 70:1994;559-563.
30. Stephens A.D., Alderman R., Chang D.et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann. Surg. Oncol. 6:1999;790-796.
31. Mongero L.B., Beck J.R., Kroslowitz R.M., Argenziano M., Chabot J.A. Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy. Perfusion. 14:1999;141-145.
32. Cavaliere F., Di Fli.ppo F., Botti C.et al. Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur. J. Surg. Oncol. 26:2000;486-491.
33. Los G., Verdegaal E., Mutsaers P., McVie G. Pentetration of carboplatin and cisplatin into rat peritoneal tumour nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28:1991;159-165.
34. Dedrick R.L., Flessner M.F., Collins J.M., Schultz J.S. A distributed model of peritoneal transport. Maher J.F., Winchester J.F. Frontiers in Peritoneal Dialysis. 1986;31 Field, Rich and Associates, New York.
35. Kerr D.J., Kaye S.B. Aspects of cytotoxic drug penetration with particular reference to anthracyclines. Cancer Chemother. Pharmacol. 19:1987;1-5.
36. Collins J.M., Dedrick R.L., Flessner M.F., Guarnio A.M. Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat. experimental observations and distributed modeling J. Pharm. Sci. 71:1982;735-738.
37. Hahn G.M., Shiu E.C. Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res. 43:1983;5789-5791.
38. Leunig M., Goetz A.E., Dellian M.et al. Interstitial fluid pressure in solid tumours following hyperthermia. possible correlation with therrapeutic response Cancer Res. 52:1992;487-490.
39. Kong G., Braun R., Dewhirst M. Hypertermia enables tumour-specific nanoparticle delivery. effect of particle size Cancer Res. 60:2000;4440-4445.
40. Mini E., Dombrowski J., Moroson B.A., Bertino J.R. Cytotoxic effects of hyperthermia, 5-fluorouracil and their combination on a human leukemia T-lymphoblast cell line, CCRF-CEM. Eur. J. Cancer Clin. Oncol. 8:1986;927-934.